转移性激素受体阳性乳腺癌的靶向治疗、测序策略及其他：美国临床肿瘤学会指南临床见解 - Suppr

Suppr

超能文献

Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.

作者信息

Makhlin Igor, Fallowfield Lesley, Henry N Lynn, Burstein Harold J, Somerfield Mark R, DeMichele Angela

机构信息

Hospital of the University of Pennsylvania, Philadelphia, PA.

University of Sussex, Brighton, United Kingdom.

出版信息

JCO Oncol Pract. 2025 Feb;21(2):140-144. doi: 10.1200/OP-24-00547. Epub 2024 Aug 27.

DOI:10.1200/OP-24-00547

PMID:39190846

Abstract

摘要

相似文献

Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.转移性激素受体阳性乳腺癌的靶向治疗、测序策略及其他：美国临床肿瘤学会指南临床见解

JCO Oncol Pract. 2025 Feb;21(2):140-144. doi: 10.1200/OP-24-00547. Epub 2024 Aug 27.

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.人表皮生长因子受体 2 阴性转移性乳腺癌患者的化疗和靶向治疗：内分泌预处理或激素受体阴性：ASCO 指南更新。

J Clin Oncol. 2021 Dec 10;39(35):3938-3958. doi: 10.1200/JCO.21.01374. Epub 2021 Jul 29.

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的内分泌治疗和靶向治疗：ASCO 指南更新。

J Clin Oncol. 2021 Dec 10;39(35):3959-3977. doi: 10.1200/JCO.21.01392. Epub 2021 Jul 29.

Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline.前列腺癌的骨骼健康和骨靶向治疗：ASCO 对安大略癌症护理指南的认可。

J Clin Oncol. 2020 May 20;38(15):1736-1743. doi: 10.1200/JCO.19.03148. Epub 2020 Jan 28.

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.内分泌治疗后或激素受体阴性转移性乳腺癌的化疗与靶向治疗：美国临床肿瘤学会指南快速推荐更新

J Clin Oncol. 2023 Feb 20;41(6):1318-1320. doi: 10.1200/JCO.22.02807. Epub 2023 Jan 10.

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.根据 2018 年 ASCO/CAP 指南，HER2 不确定乳腺癌病例重新分类为 HER2 阴性的比例，以及 HER2 不确定病例对抗 HER2 治疗的反应。

PLoS One. 2020 Nov 12;15(11):e0241775. doi: 10.1371/journal.pone.0241775. eCollection 2020.

Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update.人表皮生长因子受体2阴性转移性乳腺癌的化疗和靶向治疗：内分泌预处理或激素受体阴性患者的美国临床肿瘤学会指南快速推荐更新

J Clin Oncol. 2022 Sep 10;40(26):3088-3090. doi: 10.1200/JCO.22.01533. Epub 2022 Aug 4.

Testing for Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.检测突变以指导激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的治疗：ASCO 指南快速推荐更新。

J Clin Oncol. 2023 Jun 20;41(18):3423-3425. doi: 10.1200/JCO.23.00638. Epub 2023 May 17.

Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的内分泌和靶向治疗-卡培他滨-氟维司群：ASCO 快速推荐更新。

J Clin Oncol. 2024 Apr 20;42(12):1450-1453. doi: 10.1200/JCO.24.00248. Epub 2024 Mar 13.

Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline.在乳腺癌治疗期间和治疗后采用综合疗法：ASCO 对 SIO 临床实践指南的认可。

J Clin Oncol. 2018 Sep 1;36(25):2647-2655. doi: 10.1200/JCO.2018.79.2721. Epub 2018 Jun 11.

引用本文的文献

Phase I study of H3B-6545 in patients with estrogen receptor-positive breast cancer.H3B-6545用于雌激素受体阳性乳腺癌患者的I期研究。

ESMO Open. 2025 Jun;10(6):105290. doi: 10.1016/j.esmoop.2025.105290. Epub 2025 Jun 13.

Advancing breast cancer therapy in the era of molecular diagnostics.分子诊断时代的乳腺癌治疗进展

Breast. 2025 May 8;82:104488. doi: 10.1016/j.breast.2025.104488.

Treatment Sequencing in Metastatic HR+/HER2- Breast Cancer: A Delphi Consensus.转移性激素受体阳性/人表皮生长因子受体2阴性乳腺癌的治疗顺序：德尔菲共识

Cancers (Basel). 2025 Apr 23;17(9):1412. doi: 10.3390/cancers17091412.

PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.用于治疗雌激素受体阳性晚期乳腺癌的蛋白酶靶向嵌合体（PROTAC）雌激素受体降解剂

Target Oncol. 2025 May;20(3):431-444. doi: 10.1007/s11523-025-01137-5. Epub 2025 May 6.

Effect of Transferrin-Modified FeO Nanoparticle Targeted Delivery miR-15a-5p Combined With Photothermal Therapy on Lung Cancer.转铁蛋白修饰的FeO纳米颗粒靶向递送miR-15a-5p联合光热疗法对肺癌的影响

Thorac Cancer. 2025 Jan;16(1):e15497. doi: 10.1111/1759-7714.15497. Epub 2024 Nov 27.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验